Fennec: Japanese PEDMARK Success and Debt Elimination Drive Upside Potential and Support Buy Rating
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Fennec Pharmaceuticals with a $13.00 price target. The positive results from the Japanese Phase 2/3 trial of PEDMARK and the company's debt elimination through equity financings support this rating. The trial showed significant reduction in cisplatin-related hearing loss without compromising antitumor efficacy. The debt elimination improves Fennec's financial profile, enhancing flexibility for PEDMARK's expansion. These factors contribute to the attractive upside potential of Fennec's shares.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments